Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2

NCT04626089 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Administrative decision of the company

Conditions

Severe Acute Respiratory Syndrome Coronavirus 2
Metabolic Syndrome
Type 2 Diabetes

Interventions

DRUG: metformin glycinate
DRUG: Placebo oral tablet

Sponsor

Laboratorios Silanes S.A. de C.V.